Lilly grabs glucose-sensing insulin tech, buying Protomer in $1bn dealEli Lilly bought a stake in Protomer Technologies and its glucose-sensing insulin platform last year, and it must Share XLilly grabs glucose-sensing insulin tech, buying Protomer in $1bn dealhttps://pharmaphorum.com/news/lilly-grabs-glucose-sensing-insulin-tech-buying-protomer-in-1bn-deal/
Novo Nordisk bulks up in rare diseases with $1.2bn Prothena dealDiabetes giant Novo Nordisk has opened a new front in its rare disease R&D, thanks to an acquisition Share XNovo Nordisk bulks up in rare diseases with $1.2bn Prothena dealhttps://pharmaphorum.com/news/novo-nordisk-bulks-up-in-rare-diseases-with-1-2bn-prothena-deal/
Experts discuss the field force’s customer-centric futureThe ways in which HCPs prefer to engage with pharma has been changing for quite some time, and Share XExperts discuss the field force’s customer-centric futurehttps://pharmaphorum.com/sales-marketing/experts-discuss-the-field-forces-customer-centric-future/
FDA ends 7-year obesity drug drought, clearing Novo Nordisk’s WegovyNovo Nordisk is celebrating the FDA approval of its GLP-1 agonist semaglutide as a treatment for obesity, which Share XFDA ends 7-year obesity drug drought, clearing Novo Nordisk’s Wegovyhttps://pharmaphorum.com/news/fda-ends-obesity-drug-drought/
Novo Nordisk crowns cell therapy pipeline with $598m Heartseed dealNovo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed Share XNovo Nordisk crowns cell therapy pipeline with $598m Heartseed dealhttps://pharmaphorum.com/news/novo-nordisk-crowns-cell-therapy-pipeline-with-598m-heartseed-deal/
Trial win sets up filings for Lilly’s diabetes blockbuster hope tirzepatideEli Lilly has scored five out of five with its phase 3 trials of type 2 diabetes candidate Share XTrial win sets up filings for Lilly’s diabetes blockbuster hope tirzepatidehttps://pharmaphorum.com/news/final-trial-win-sets-up-filings-for-lillys-diabetes-blockbuster-hope-tirzepatide/
Novo Nordisk moves chronic kidney disease drug ziltivekimab into phase 3Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic Share XNovo Nordisk moves chronic kidney disease drug ziltivekimab into phase 3https://pharmaphorum.com/news/novo-nordisk-moves-chronic-kidney-disease-drug-ziltivekimab-into-phase-3/
Arecor hopes London stock market float will raise profile of insulin productsUK biotech Arecor Therapeutics has announced plans to float on the London stock market, to fund plans to Share XArecor hopes London stock market float will raise profile of insulin productshttps://pharmaphorum.com/news/arecor-hopes-london-stock-market-float-will-raise-profile-of-insulin-products/
Novo Nordisk ups forecasts after Q1 profit boostAfter an indifferent period Novo Nordisk has kicked off 2021 on the front foot, raising its financial forecast Share XNovo Nordisk ups forecasts after Q1 profit boosthttps://pharmaphorum.com/news/novo-nordisk-ups-forecasts-after-q1-profit-boost/
